LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Tabassum, Aniqa"
  2. AU="Lee, Su Jeong"
  3. AU="Chen, Huiling"
  4. AU="Nie, Wanyi"
  5. AU="Emami, Maryam Sadat" AU="Emami, Maryam Sadat"
  6. AU="Steegers, Eric"
  7. AU="Perkins, Jennifer"
  8. AU="Chen, Baibing"
  9. AU="Sadeghi, Balal"
  10. AU="Katerina Galai"
  11. AU="Barracchia, Carlo Giorgio"
  12. AU="Reeves, Jason W"
  13. AU="Lozano, Idalys"
  14. AU="Donner, Kati M"
  15. AU="Fauré, A"

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Indirect Calorimetry to Measure Metabolic Rate and Energy Expenditure in Psychiatric Populations: A Systematic Review.

    Di Vincenzo, Joshua Daniel / O'Brien, Liam / Jacobs, Ira / Jawad, Muhammad Youshay / Ceban, Felicia / Meshkat, Shakila / Gill, Hartej / Tabassum, Aniqa / Phan, Lee / Badulescu, Sebastian / Rosenblat, Joshua Daniel / McIntyre, Roger S / Mansur, Rodrigo B

    Nutrients

    2023  Volume 15, Issue 7

    Abstract: Psychiatric and metabolic disorders are highly comorbid and the relationship between these disorders is bidirectional. The mechanisms underlying the association between psychiatric and metabolic disorders are presently unclear, which warrants ... ...

    Abstract Psychiatric and metabolic disorders are highly comorbid and the relationship between these disorders is bidirectional. The mechanisms underlying the association between psychiatric and metabolic disorders are presently unclear, which warrants investigation into the dynamics of the interplay between metabolism, substrate utilization, and energy expenditure in psychiatric populations, and how these constructs compare to those in healthy controls. Indirect calorimetry (IC) methods are a reliable, minimally invasive means for assessing metabolic rate and substrate utilization in humans. This review synthesizes the extant literature on the use of IC on resting metabolism in psychiatric populations to investigate the interaction between psychiatric and metabolic functioning. Consistently, resting energy expenditures and/or substrate utilization values were significantly different between psychiatric and healthy populations in the studies contained in this review. Furthermore, resting energy expenditure values were systematically overestimated when derived from predictive equations, compared to when measured by IC, in psychiatric populations. High heterogeneity between study populations (e.g., differing diagnoses and drug regimens) and methodologies (e.g., differing posture, time of day, and fasting status at measurement) impeded the synthesis of results. Standardized IC protocols would benefit this line of research by enabling meta-analyses, revealing trends within and between different psychiatric disorders.
    MeSH term(s) Humans ; Calorimetry, Indirect/methods ; Energy Metabolism ; Calorimetry ; Rest ; Mental Disorders ; Basal Metabolism
    Language English
    Publishing date 2023-03-30
    Publishing country Switzerland
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 2518386-2
    ISSN 2072-6643 ; 2072-6643
    ISSN (online) 2072-6643
    ISSN 2072-6643
    DOI 10.3390/nu15071686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review.

    Jawad, Muhammad Youshay / Qasim, Saleha / Ni, Menglu / Guo, Ziji / Di Vincenzo, Joshua D / d'Andrea, Giacomo / Tabassum, Aniqa / Mckenzie, Andrea / Badulescu, Sebastian / Grande, Iria / McIntyre, Roger S

    Brain sciences

    2023  Volume 13, Issue 6

    Abstract: Bipolar depression remains a clinical challenge with a quarter of patients failing to respond to initial conventional treatments. Although ketamine has been extensively studied in unipolar depression, its role in bipolar disorder remains inconclusive. ... ...

    Abstract Bipolar depression remains a clinical challenge with a quarter of patients failing to respond to initial conventional treatments. Although ketamine has been extensively studied in unipolar depression, its role in bipolar disorder remains inconclusive. The aim of our scoping review was to comprehensively synthesize the current clinical literature around ketamine use in bipolar depression. A total of 10 clinical studies (5 randomized controlled trials and 5 open label studies) were selected. The preliminary evidence, albeit weak, suggests that ketamine is a promising treatment and calls for further interest from the research community. Overall, ketamine treatment appeared to be tolerable with minimal risk for manic/hypomanic switching and showed some effectiveness across parameters of depression and suicidality. Moreover, ketamine is a potential treatment agent in patients with treatment-resistant bipolar depression with promising data extracted from extant controlled trials and real-world effectiveness studies. Future studies are needed to identify ketamine's role in acute and maintenance treatment phases of bipolar depression. Moreover, future researchers should study the recurrence prevention and anti-suicidal effects of ketamine in the treatment of bipolar depression.
    Language English
    Publishing date 2023-06-04
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2651993-8
    ISSN 2076-3425
    ISSN 2076-3425
    DOI 10.3390/brainsci13060909
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression.

    Fancy, Farhan / Rodrigues, Nelson B / Di Vincenzo, Joshua D / Chau, Edmond H / Sethi, Rickinder / Husain, Muhammad I / Gill, Hartej / Tabassum, Aniqa / Mckenzie, Andrea / Phan, Lee / McIntyre, Roger S / Rosenblat, Joshua D

    Focus (American Psychiatric Publishing)

    2023  Volume 21, Issue 4, Page(s) 420–429

    Abstract: Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness ... ...

    Abstract Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Methods: This study was conducted in a community clinic in Mississauga, Ontario (Canadian Rapid Treatment Centre of Excellence; Braxia Health). In this observational study (NCT04209296), patients with treatment-resistant bipolar I/II depression (
    Results: Statistically and clinically significant antidepressant effects were observed in the overall sample, as measured by the Quick Inventory for Depression Symptomatology-Self Report-16 (QIDS-SR
    Conclusions: Real-world effectiveness of IV ketamine for bipolar depression was observed. Repeated doses were associated with greater symptom reduction and adequate tolerability.Reprinted from
    Language English
    Publishing date 2023-10-15
    Publishing country United States
    Document type Journal Article
    ISSN 1541-4094
    ISSN 1541-4094
    DOI 10.1176/appi.focus.23021022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.

    Chisamore, Noah / Danayan, Kevork / Rodrigues, Nelson B / Di Vincenzo, Joshua D / Meshkat, Shakila / Doyle, Zoe / Mansur, Rodrigo / Phan, Lee / Fancy, Farhan / Chau, Edmond / Tabassum, Aniqa / Kratiuk, Kevin / Arekapudi, Anil / McIntyre, Roger S / Rosenblat, Joshua D

    Journal of psychopharmacology (Oxford, England)

    2023  Volume 37, Issue 8, Page(s) 775–783

    Abstract: Background: Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age ...

    Abstract Background: Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age 18-25) populations remains understudied.
    Methods: In this retrospective analysis, TAY patients (
    Results: A significant main effect of infusions on reduction of total QIDS-SR16 (
    Conclusion: Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.
    MeSH term(s) Adult ; Humans ; Adolescent ; Young Adult ; Middle Aged ; Ketamine/adverse effects ; Depression/diagnosis ; Retrospective Studies ; Depressive Disorder, Treatment-Resistant/drug therapy ; Depressive Disorder, Treatment-Resistant/diagnosis ; Infusions, Intravenous
    Chemical Substances Ketamine (690G0D6V8H)
    Language English
    Publishing date 2023-05-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 639313-5
    ISSN 1461-7285 ; 0269-8811
    ISSN (online) 1461-7285
    ISSN 0269-8811
    DOI 10.1177/02698811231171531
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2311: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.

    Danayan, Kevork / Chisamore, Noah / Rodrigues, Nelson B / Vincenzo, Joshua D Di / Meshkat, Shakila / Doyle, Zoe / Mansur, Rodrigo / Phan, Lee / Fancy, Farhan / Chau, Edmond / Tabassum, Aniqa / Kratiuk, Kevin / Arekapudi, Anil / Teopiz, Kayla M / McIntyre, Roger S / Rosenblat, Joshua D

    Psychiatry research

    2023  Volume 323, Page(s) 115133

    Abstract: Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders, including treatment-resistant depression (TRD). Comorbidity of BPD with depression is associated with poorer response to antidepressants. Intravenous ketamine is a ... ...

    Abstract Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders, including treatment-resistant depression (TRD). Comorbidity of BPD with depression is associated with poorer response to antidepressants. Intravenous ketamine is a novel treatment for TRD that has not been specifically evaluated in patients with comorbid BPD. In this retrospective analysis of data collected from participants who received care at the Canadian Rapid Treatment Centre of Excellence (CRTCE; Braxia Health; ClinicalTrials.gov: NCT04209296), we evaluated the effectiveness of intravenous ketamine in a TRD population with comorbid BPD (N=100; n=50 BPD-positive compared with n=50 BPD-negative). Participants were administered four doses of intravenous ketamine (0.5-0.75mg/kg over 40 minutes) over two weeks. The primary outcome measures were changes in depressive symptom severity (as measured by Quick Inventory of Depressive Symptomatology-Self Report 16-item (QIDS-SR
    MeSH term(s) Humans ; Borderline Personality Disorder/complications ; Borderline Personality Disorder/drug therapy ; Borderline Personality Disorder/epidemiology ; Canada/epidemiology ; Depression/epidemiology ; Depressive Disorder, Treatment-Resistant/complications ; Depressive Disorder, Treatment-Resistant/drug therapy ; Depressive Disorder, Treatment-Resistant/epidemiology ; Ketamine/pharmacology ; Ketamine/therapeutic use ; Retrospective Studies
    Chemical Substances Ketamine (690G0D6V8H)
    Language English
    Publishing date 2023-03-05
    Publishing country Ireland
    Document type Clinical Trial ; Journal Article
    ZDB-ID 445361-x
    ISSN 1872-7123 ; 1872-7506 ; 0925-4927 ; 0165-1781
    ISSN (online) 1872-7123 ; 1872-7506
    ISSN 0925-4927 ; 0165-1781
    DOI 10.1016/j.psychres.2023.115133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.

    Fancy, Farhan / Rodrigues, Nelson B / Di Vincenzo, Joshua D / Chau, Edmond H / Sethi, Rickinder / Husain, Muhammad I / Gill, Hartej / Tabassum, Aniqa / Mckenzie, Andrea / Phan, Lee / McIntyre, Roger S / Rosenblat, Joshua D

    Bipolar disorders

    2022  Volume 25, Issue 2, Page(s) 99–109

    Abstract: Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness ... ...

    Abstract Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Methods: This study was conducted in a community clinic in Mississauga, Ontario (Canadian Rapid Treatment Centre of Excellence; Braxia Health). In this observational study (NCT04209296), patients with treatment-resistant bipolar I/II depression (n = 66) received four sub-anesthetic doses of IV ketamine (0.5-0.75 mg/kg) over a two-week period. Symptoms of depression, suicidality, anxiety, and functioning were assessed with validated self-report measures.
    Results: Statistically and clinically significant antidepressant effects were observed in the overall sample, as measured by the Quick Inventory for Depression Symptomatology-Self Report-16 (QIDS-SR
    Conclusions: Real-world effectiveness of IV ketamine for bipolar depression was observed. Repeated doses were associated with greater symptom reduction and adequate tolerability.
    MeSH term(s) Humans ; Ketamine ; Bipolar Disorder/drug therapy ; Depressive Disorder, Major/diagnosis ; Canada ; Antidepressive Agents/therapeutic use ; Depressive Disorder, Treatment-Resistant/drug therapy ; Infusions, Intravenous ; Depression/diagnosis
    Chemical Substances Ketamine (690G0D6V8H) ; Antidepressive Agents
    Language English
    Publishing date 2022-12-26
    Publishing country Denmark
    Document type Observational Study ; Journal Article
    ZDB-ID 1472242-2
    ISSN 1399-5618 ; 1398-5647
    ISSN (online) 1399-5618
    ISSN 1398-5647
    DOI 10.1111/bdi.13284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5604: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.

    Jawad, Muhammad Youshay / Di Vincenzo, Joshua D / Badulescu, Sebastian / Teopiz, Kayla M / Tabassum, Aniqa / Ceban, Felicia / Mckenzie, Andrea / Meshkat, Shakila / Rosenblat, Joshua D / Ho, Roger C / McIntyre, Roger S

    Neuropharmacology

    2022  Volume 223, Page(s) 109299

    Abstract: Over the past two decades, ketamine has emerged as a novel effective and rapid-acting antidepressant. While the vast majority of studies on ketamine have focused on its ability to reduce the severity of depression broadly, its effectiveness in specific ... ...

    Abstract Over the past two decades, ketamine has emerged as a novel effective and rapid-acting antidepressant. While the vast majority of studies on ketamine have focused on its ability to reduce the severity of depression broadly, its effectiveness in specific domains such as cognition, anhedonia, suicidality, and workplace/social/scholastic functionality has been neglected. Similarly, current treatments (e.g., SSRIs and SNRIs) aim to improve overall depression severity, which often results in the persistence of one or more residual symptom domains and prevents full recovery to premorbid functionality. In this review, we narratively synthesize the literature pertaining to the effectiveness of ketamine in treating key domains of depressive symptomatology (i.e., cognition, anhedonia, suicidality, and psychosocial functionality). Our findings suggest that ketamine is effective across domains varyingly, with the strongest evidence being for its ability to reduce suicidality. The rapid acting nature of ketamine further supports its use in treating suicidality and potentially preventing the completion of suicide. Evidence for the effectiveness of ketamine in other domains is weak, primarily due to a lack of robust studies specifically designed to assess these domains as primary outcomes. Future studies should scrutinize the effects of ketamine on specific domains of depression to optimize its implementation.
    Language English
    Publishing date 2022-11-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 218272-5
    ISSN 1873-7064 ; 0028-3908
    ISSN (online) 1873-7064
    ISSN 0028-3908
    DOI 10.1016/j.neuropharm.2022.109299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui I Zs.242: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: The bidirectional association of nonalcoholic fatty liver disease with depression, bipolar disorder, and schizophrenia.

    Jawad, Muhammad Youshay / Meshkat, Shakila / Tabassum, Aniqa / Mckenzie, Andrea / Di Vincenzo, Joshua D / Guo, Ziji / Musavi, Nabiha Batool / Phan, Lee / Ceban, Felicia / Kwan, Angela Th / Ramachandra, Ranuk / Le, Gia Han / Mansur, Rodrigo B / Rosenblat, Joshua D / Ho, Roger / Rhee, Taeho Greg / McIntyre, Roger S

    CNS spectrums

    2022  Volume 28, Issue 5, Page(s) 541–560

    Abstract: Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic-inflammatory disease associated with poor outcomes and decreased quality of life. NAFLD is overrepresented in patients with psychiatric disorders like depression, bipolar disorder, and ... ...

    Abstract Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic-inflammatory disease associated with poor outcomes and decreased quality of life. NAFLD is overrepresented in patients with psychiatric disorders like depression, bipolar disorder, and schizophrenia; however, a comprehensive review on NAFLD and psychiatric disorders remains to be delineated. This review endeavors to investigate the association of NAFLD with psychiatric disorders, including shared pathogenesis and future clinical derivatives. Extant literature suggests that patients with psychiatric disorders (in particular, mood disorders) are more susceptible to the development of NAFLD due to multiple reasons, including but not limited to hypothalamic-pituitary-adrenal axis dysregulation, metabolic syndrome, and chronic perceived stress. Moreover, the clinical manifestations of mood disorders (e.g., anhedonia, psychomotor retardation, lifestyle modification, etc.), and potentially long-term treatment with weight-gaining agents, differentially affect these patients, making them more prone to NAFLD. Considering the increased morbidity associated with both mood disorders and NAFLD, our review recommends regular screenings for NAFLD in select patients with mood disorders exhibiting signs of increased risk (i.e., obesity, metabolic syndrome, diabetes, or family history of NAFLD) for better diagnosis and holistic care of both potentially interrelated conditions.
    Language English
    Publishing date 2022-10-21
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2008418-3
    ISSN 2165-6509 ; 1092-8529
    ISSN (online) 2165-6509
    ISSN 1092-8529
    DOI 10.1017/S1092852922001043
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5171: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 340: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top